Risk Factors for the Exacerbation of Esophageal Varices in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma
Oncology · 2025
DOI: 10.1159/000548667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Hitomi Takada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan, takadahi0107@gmail.c…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Esophageal and Gastric Varices, Bevacizumab. Die Arbeit nennt 57 Literaturangaben.
Abstract (Originalsprache)
Introduction
Atezolizumab plus bevacizumab (AB) therapy is an effective systemic therapy for unresectable hepatocellular carcinoma (u-HCC). However, exacerbations of esophageal varices (EV) often occur, and EV management should be clarified to attain a better prognosis in patients with u-HCC. Our research aimed to explore the actual situation of EV exacerbation and its risk factors in patients receiving AB therapy.
Methods
We recruited 82 patients receiving AB therapy for u-HCC. All patients underwent esophagogastroduodenoscopy (EGD) within 3 months before AB induction to assess EV presence. The emergence of EV findings requiring urgent or planned endoscopic treatment defined EV exacerbation. The frequency and risk factors for EV exacerbation after AB introduction were analyzed.
Results
Of the participants, 49% had EV findings on preinduction EGD. Within the observation period, 17% had EV exacerbation, and 7.2% experienced rupture. Among those with EV exacerbation, 7 had positive red color signs, and 1 had formal deterioration to F3. In EV rupture, 4 had eruptive hemorrhage, 1 had gushing hemorrhage, and 1 had a white plug. Independent factors requiring therapeutic intervention for EV exacerbation were EV treatment history, drug-resistant ascites effusion, esophageal intramural vessel (EIV) diameter >3.3 mm, and left gastric vein (LGV) diameter >4.9 mm on computed tomography (CT) scan.
Conclusion
Patients with EV treatment history, drug-resistant ascites effusion, and EIV and LGV diameters >3.3 and 4.9 mm via CT, respectively, may require careful monitoring for possible EV exacerbation, enabling better EV management, adequate AB therapy, and finally, prolonged patient survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology and Hepatology Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan, takadahi0107@gmail.com.
- Gastroenterology and Hepatology Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Zitieren
APA
Takada, H., Osawa, L., Komiyama, Y., Muraoka, M., Suzuki, Y., Sato, M., Kobayashi, S., Yoshida, T., Takano, S., Maekawa, S., Tsuchiya, A., & Enomoto, N. (2025). Risk Factors for the Exacerbation of Esophageal Varices in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. Oncology. https://doi.org/10.1159/000548667
Vancouver
Takada H, Osawa L, Komiyama Y, Muraoka M, Suzuki Y, Sato M, et al. Risk Factors for the Exacerbation of Esophageal Varices in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. Oncology. 2025. doi:10.1159/000548667
BibTeX
@article{Takada2025,
author = {Takada, Hitomi and Osawa, Leona and Komiyama, Yasuyuki and Muraoka, Masaru and Suzuki, Yuichiro and Sato, Mitsuaki and Kobayashi, Shoji and Yoshida, Takashi and Takano, Shinichi and Maekawa, Shinya and Tsuchiya, Atsunori and Enomoto, Nobuyuki},
title = {Risk Factors for the Exacerbation of Esophageal Varices in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma},
journal = {Oncology},
year = {2025},
doi = {10.1159/000548667}
}
EUVIMED